Randomised double-blind placebo-controlled study of interferon -1a in relapsing/remitting multiple sclerosis
Background Previous trials of interferon in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate the effects of subcutaneous interferon -1a. Methods 560 patients with Kurtzke expanded disability status scale (EDSS) scores of